137 related articles for article (PubMed ID: 10606174)
1. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas.
Hagel C; Krog B; Laas R; Stavrou DK
J Exp Clin Cancer Res; 1999 Sep; 18(3):305-9. PubMed ID: 10606174
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
5. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas.
Kros JM; Hop WC; Godschalk JJ; Krishnadath KK
Cancer; 1996 Sep; 78(5):1107-13. PubMed ID: 8780550
[TBL] [Abstract][Full Text] [Related]
7. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis of presumptive prognostic markers among oligodendrogliomas.
McLendon RE; Herndon JE; West B; Reardon D; Wiltshire R; Rasheed BK; Quinn J; Friedman HS; Friedman AH; Bigner DD
Cancer; 2005 Oct; 104(8):1693-9. PubMed ID: 16116609
[TBL] [Abstract][Full Text] [Related]
10. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
[TBL] [Abstract][Full Text] [Related]
11. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
Talley L; Chhieng DC; Bell WC; Grizzle WE; Frost AR
Biotech Histochem; 2008 Feb; 83(1):5-14. PubMed ID: 18568671
[TBL] [Abstract][Full Text] [Related]
13. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
14. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung.
Demarchi LM; Reis MM; Palomino SA; Farhat C; Takagaki TY; Beyruti R; Saldiva PH; Capelozzi VL
Mod Pathol; 2000 May; 13(5):511-20. PubMed ID: 10824922
[TBL] [Abstract][Full Text] [Related]
15. Ki-67, p53 and bcl-2 analysis in colonic versus rectal adenocarcinoma.
Petrişor O; Giuşcă SE; Sajin M; Dobrescu G; Căruntu ID
Rom J Morphol Embryol; 2008; 49(2):163-71. PubMed ID: 18516322
[TBL] [Abstract][Full Text] [Related]
16. Implications of prognostic markers in brain tumors.
Grzybicki DM; Moore SA
Clin Lab Med; 1999 Dec; 19(4):833-47. PubMed ID: 10572718
[TBL] [Abstract][Full Text] [Related]
17. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays.
Engellau J; Bendahl PO; Persson A; Domanski HA; Akerman M; Gustafson P; Alvegård TA; Nilbert M; Rydholm A
Hum Pathol; 2005 Sep; 36(9):994-1002. PubMed ID: 16153463
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
[TBL] [Abstract][Full Text] [Related]
19. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas.
Nayak A; Ralte AM; Sharma MC; Singh VP; Mahapatra AK; Mehta VS; Sarkar C
Neurol India; 2004 Jun; 52(2):228-32. PubMed ID: 15269478
[TBL] [Abstract][Full Text] [Related]
20. Ki-67, cyclin D1, p53 and bcl-2 expression in advanced head and neck cancer.
Nagy B; Tiszlavicz L; Eller J; Molnar J; Thurzo L
In Vivo; 2003; 17(1):93-6. PubMed ID: 12655798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]